Open Nav

Scientific Focused Sessions

  • Cancer Epigenetics and Emerging Therapies
  • Ten years after the sequencing of the human genome, the use of epigenetics in developing targeted cancer treatments is rapidly growing. What are recent discoveries in epigenetic abnormalities and what are the implications for cancer treatment? What emerging therapies are on the forefront of this new and cutting-edge research?
  • Treating NSCLC in China 
  • Lung cancer is the leading cause of death in the world and prevalence of NSCLC in China is no exception. Prominent oncologists from both the clinic and the bench will provide their insights on this growing treatment market. How do branded Western drugs fare against the Chinese competitors? Which drugs currently dominate the Chinese NSCLC market and how will the market continue to grow?
  • Traditional Chinese Medicine
  • China has used Traditional Chinese Medicine (TCM) for centuries and still comprises a substantial portion of the Chinese healthcare industry. How are these medicines used in China and what are the opportunities for TCM outside of China?
  • Diabetes Dx and Treatment in China
  • As the prevalence of diabetes continues to rise in China, the country plans to enact regulations to screen high-risk populations, necessitating the availability of more treatments across the country. Several pharmacos have already increased their distribution and manufacturing capabilities of these new medications. What’s in the diagnostics pipeline for identifying these at-risk populations? What is currently the standard of care and how will that change in the next few years?
  • Respiratory Disease in China—Treatment and Prevention
  • According to the World Health Organization (WHO), chronic respiratory disease is the 2nd leading cause of death in China. Chronic obstructive pulmonary disease (COPD) is rapidly increasing as a public health concern in the country, necessitating proper education, diagnosis and treatment. This panel will explore current treatment paradigms, both in TCM and western medicine, in addition to current research and prevention mechanisms.
  • Vaccines 
  • Hand, foot, and mouth disease continues to represent a significant unmet public health need and economic burden in China, as well as several other Asian countries. Flu also continues to be rampant in China. What vaccines are being used and what vaccines are in late stage development that can be leveraged in the at-risk populations in China?
  • Rare Diseases in China  
  • The establishment of China’s first national organization against rare diseases (China Rare Diseases Prevention & Treatment Alliance) reaffirms the country’s commitment to innovative health care research. China is actively promoting the regulation of rare diseases and orphan drugs. This panel will focus on the research and development of orphan drugs in China.